Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

[ Special series on Gynecological Tumor ]
doi: 10.5732/cjc.014.10274
Ovarian cancer standard of care: are there real alternatives?
Chiara Della Pepa, Giuseppe Tonini, Carmela Pisano, Marilena Di Napoli, Sabrina Chiara Cecere, Rosa Tambaro, Gaetano Facchini, Sando Pignata
Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro Del Portillo, 200, Rome 00128, Italy
[Abstract] Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple (primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase (PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient’s clinical condition and disease state, continue to gain importance in guiding treatment choices.
Chinese Journal of Cancer 2015, Volume: 34, Issue 1, Page: 17-27
[ PDF Full-text ]
[ Html full-text ](PubMed Central)

[ PubMed ]

[Google Scholar]


[ More articles of the special series on Gynecological Tumor ]


Cite this article

Chiara Della Pepa, Giuseppe Tonini, Carmela Pisano, Marilena Di Napoli, Sabrina Chiara Cecere, Rosa Tambaro, Gaetano Facchini, Sando Pignata. Ovarian cancer standard of care: are there real alternatives?. Chin J Cancer. 2015, 34(1):17-27. doi:10.5732/cjc.014.10274


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China